U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. Minjun Chen
  1. Science & Research (NCTR)

Minjun Chen Ph.D.

Staff Fellow — Division of Bioinformatics and Biostatistics

Minjun Chen
Minjun Chen, Ph.D.

(870) 543-7391
NCTRResearch@fda.hhs.gov  

Back to NCTR Principal Investigators page


 About Publications  |  Lab Members


Background

Dr. Minjun Chen received his Ph.D. degree from Zhejiang University, China in 2003. Starting in 2003, he worked as an assistant professor at the School of Pharmacy at Shanghai JiaoTong University in China, and was promoted to associate professor in 2005. In November 2006, Dr. Chen came to NCTR as a postdoctoral fellow jointly with the University of Medicine and Dentistry of New Jersey. He was promoted to an FDA staff fellow in the division in October 2008 and currently is a staff fellow in the division. During his research career, Dr. Chen has been the author or co-author of 78 peer-reviewed research articles, one book as the editor, six book chapters, and four technical reports. His work has been cited 3,277 times with an H-index of 31 based on the Google Scholar search as of June 7, 2018. He received the FDA award for “Outstanding Junior Investigator” in 2012, the NCTR “Scientific Achievement Award” in 2014, and the FDA "Scientific Achievement Award for Excellence in Analytical Science" in 2017. He established and currently co-chairs the FDA Liver Toxicity Working Group (LTWG) which is officially endorsed by the Office of the Chief Scientist with 60 FDA scientists involved to gather the expertise of drug-induced liver injury (DILI) within FDA. Dr. Chen is the editor of a book titled “Drug-Induced Liver Injury” with 92 contributing scientists from U.S. and EU, and published by Humana Press, Springer in 2018.


Research Interests

Dr. Chen's primary research interests encompass bioinformatics, drug safety, biomarker discovery, and toxicogenomics. His current research focus is in two areas:

  • Development of the Liver Toxicity Knowledge Base to address the concerns related to drug-induced liver injury  from public health and regulatory agencies.

  • Identification of biomarkers for predicting the outcome of chemotherapy of breast-cancer patients in support of precision medicine.


Professional Societies/National and International Groups

Mid-South Computational Biology & Bioinformatics Society
Member
2008 – Present

Society of Toxicology (SOT)
Member
2008 – Present

Council of Computational Toxicological Special Section, SOT 
Member
2018 – Present

BACK TO TOP


Select Publications

Publication titles are linked to text abstracts on PubMed.

Drug-Induced Liver Toxicity.disclaimer icon
Chen M. and Will Y.
Humana Press. 2018.
 

Therapeutic Bile Acids and the Risks for Hepatotoxicity.disclaimer icon
Ashby K., Navarro Almario E.E., Tong W., Borlak J., Mehta R., and Chen M.
Alimentary Pharmacology & Therapeutics. 2018 Apr.
 

Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?
Mishra P. and Chen M.
Gastroenterology. 2017 May, 152 (6): 1270-1274.
 

A Model to Predict Severity of Drug-Induced Liver Injury in Humans.
Chen M., Borlak J., and Tong W.
Hepatology. 2016 Sep, 64(3):931-40. 
 

DILIrank: The Largest Reference Drug List Ranked by the Risk for Developing Drug-Induced Liver Injury in Humans.
Chen M., Suzuki A., Thakkar S., Yu K., Hu C., and Tong W.
Drug Discov Today. 2016 Apr, 21(4):648-53. doi: 10.1016/j.drudis.2016.02.015. Epub 2016 Mar 3.
 

Drug-Induced Liver Injury: Interactions Between Drug Properties and Host Factors.
Chen M., Suzuki A., Borlak J., Andrade R.J., and Lucena M.I.
J Hepatol. 2015 Aug, 63(2):503-14.
 

A Testing Strategy to Predict Risk for Drug-Induced Liver Injury in Humans Using High-Content Screen Assays and the 'Rule-of-Two' Model.
Chen M., Tung C.W., Shi Q., Guo L., Shi L., Fang H., Borlak J., and Tong W.
Arch Toxicol. 2014 Jul, 88(7):1439-49.
 

Quantitative Structure-Activity Relationship Models for Predicting Drug-Induced Liver Injury Based on FDA-Approved Drug Labeling Annotation and Using a Large Collection of Drugs.
Chen M., Hong H., Fang H., Kelly R., Zhou G., Borlak J., and Tong W.
Toxicol Sci. 2013 Nov, 136(1):242-9.
 

High Lipophilicity and High Daily Dose of Oral Medications Are Associated with Significant Risk for Drug-Induced Liver Injury.
Chen M., Borlak J., and Tong W.
Hepatology. 2013 Jul, 58(1):388-96.
 

The Liver Toxicity Knowledge Base: A Systems Approach to a Complex End Point.
Chen M., Zhang J., Wang Y., Liu Z., Kelly R., Zhou G., Fang H., Borlak J., and Tong W.
Clin Pharmacol Ther. 2013 May, 93(5):409-12.
 

A Decade of Toxicogenomic Research and Its Contribution to Toxicological Science.
Chen M., Zhang M., Borlak J., and Tong W.
Toxicol Sci. 2012 Dec, 130(2):217-28.
 

FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury.
Chen M., Vijay V., Shi Q., Liu Z., Fang H., and Tong W.
Drug Discov Today. 2011 Aug, 16(15-16):697-703.
 

BACK TO TOP


Lab Members

Contact information for all lab members:
(870) 543-7391
NCTRResearch@fda.hhs.gov

Kristin Mecuen
Ph.D. Candidate

Jieqiang Zhu, Ph.D.
ORISE Fellow
 


BACK TO TOP
 


Contact Information
Minjun Chen
(870) 543-7391
Expertise
Approach